SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect ...
ARS Pharmaceuticals Inc (SPRY) stock saw a decline, ending the day at $14.77 which represents a decrease of $-0.09 or -0.61% from the prior close of $14.86. The stock opened at $14.97 and touched a ...
SAN DIEGO - ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)已提交一份补充新药申请(sNDA),用于neffy® 1 mg,这是一种针对体重15至30公斤(33-66磅)儿童的无针式肾上腺素治疗,用于I型过敏反应,包括过敏性休克。此次提交是在FDA于2024年8月9日批准用于30公斤或以上患者的neffy 2 mg之后进行的。 该公司报告称,neffy ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
ARS Pharmaceuticals Inc (SPRY) stock saw a modest uptick, ending the day at $14.05 which represents a slight increase of $1.00 or 7.66% from the prior close of $13.05. The stock opened at $13.1 and ...